Acetazolamide is an enzyme inhibitor, which acts specifically on carbonic anhydrase. Acetazolamide, sold under the trade name Diamox, is used to treat glaucoma, altitude sickness, epilepsy, fluid retention, heart failure, and seizures.

In addition to this, acetazolamide (carbonic anhydrase inhibitor) is effective in controlling fluid secretions, to treat certain convulsive disorders, and promotes diuresis in instances of abnormal fluid retention such as cardiac edema.

Increasing effectiveness of acetazolamide in treating other indication such as drug induced edema and brain tumor glioblastoma is offering growth prospective for key drug manufacturers in this market. For instance, according to a new study published in Science Translational Medicine Journal in July 2018, acetazolamide may also be effective in treating glioblastoma, fast-growing brain tumor. As per the study findings, acetazolamide can restore temozolomide’s (TMZ) ability to kill tumor cells. Furthermore, the study suggested that the combination of acetazolamide with TMZ may be an effective subgroup to consider for trial for patients with high BCL-3 expression.

Market Dynamics

Increasing prevalence of glaucoma and its risk factors among global population is propelling demand for acetazolamide during the forecast period. Moreover, acetazolamide is commonly used for preventing high altitude illness, this increases the utility of the drug. 

For instance, according to the International Journal of Advanced Medical and Health Research, 2015, glaucoma is seen to be the second major reason causing blindness among people across the world, followed by cataract.

Furthermore, according to the BrightFocus Foundation, June 2017 data findings, over 3 million Americans suffer from glaucoma, out of which 2.7 million (aged 40 and older) are affected by its most common form, open-angle glaucoma. Also, high prevalence of eye disorder in the geriatric population and nutritional deficiency in the younger population due to changing food habits are other factors affecting the health of the people globally, which might lead to boost growth of acetazolamide market. Acetazolamide capsule taken once a day by patients with chronic glaucoma offers a substantial pressure-lowering effect, which lasts at least 23 hours.

Acetazolamide helps in preventing acute mountain sickness and has fewer side effects than alternative drugs such as dexamethasone, which can mask symptoms and therefore carries greater risk.  

Key features of the study

• This report provides in-depth analysis of acetazolamide market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2026 – 2033), considering 2025, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, drug approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global acetazolamide market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as part of this study include Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage Pharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories Ltd., Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.), Lannett Company, Inc., Strides Shasun Limited, and X-GEN Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
• The global acetazolamide market report caters to various stakeholders in this industry including investors, suppliers, acetazolamide based product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the acetazolamide market.

Market Segmentation

• By Formulation Insights (Revenue, US$ Mn, 2021 - 2033)
  • Tablets
  • Capsules
  • Injection
• By Application Insights (Revenue, US$ Mn, 2021 - 2033)
  • Glaucoma
  • Epilepsy
  • Drug-induced Edema
  • Altitude Sickness
  • Fluid Retention
  • Heart Failure and Seizures
• By Distribution Channel Insights (Revenue, US$ Mn, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region Insights (Revenue, US$ Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players in the Acetazolamide Market
  • Teva Pharmaceutical Industries Ltd.
  • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
  • Heritage Pharmaceuticals Inc.
  • Nostrum Laboratories Inc.
  • Novast Laboratories Ltd.
  • Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.)
  • Lannett Company, Inc.
  • Strides Shasun Limited
  • X-GEN Pharmaceuticals, Inc.